Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP5 | Q01469 | 6/20 | 0.58 |
| ▸ | FABP7 | O15540 | 4/20 | 0.58 |
| ▸ | FABP3 | P05413 | 3/20 | 0.58 |
| ▸ | SLC18A3 | Q16572 | 4/20 | 0.45 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.43 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.43 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9370830 | 1.00 | FABP5 (0.58) | FABP5FABP7FABP3SLC18A3KCNQ3 | |
| SCHEMBL27688008 | 0.86 | FABP5 (0.57) | FABP5FABP7FABP3SLC18A3KCNQ3 | |
| SCHEMBL28635740 | 0.86 | FABP5 (0.57) | FABP5FABP7FABP3SLC18A3KCNQ3 | |
| SCHEMBL7433049 | 0.86 | FABP5 (0.57) | FABP5FABP7FABP3SLC18A3KCNQ3 | |
| SCHEMBL28644515 | 0.86 | FABP5 (0.57) | FABP5FABP7FABP3SLC18A3KCNQ3 | |
| SCHEMBL7433046 | 0.86 | FABP5 (0.57) | FABP5FABP7FABP3SLC18A3KCNQ3 | |
| SCHEMBL7433044 | 0.86 | FABP5 (0.57) | FABP5FABP7FABP3SLC18A3KCNQ3 | |
| SCHEMBL28635739 | 0.86 | FABP5 (0.57) | FABP5FABP7FABP3SLC18A3KCNQ3 | |
| SCHEMBL25369789 | 0.83 | FABP5 (0.64) | FABP5FABP7FABP3SLC18A3KCNQ3 | |
| SCHEMBL21825849 | 0.83 | FABP5 (0.64) | FABP5FABP7FABP3SLC18A3KCNQ3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6835746-B2 | For therapy of cancer | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | 2004-12-28 | — | — | US | disclosed |
| US-20030232878-A1 | Taxoid anti-tumor agents and pharmaceutical compositions thereof | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | 2003-12-18 | — | — | US | disclosed |
| US-6500858-B2 | FOR THERAPY OF CANCER | THE RESEARCH FOUNDATION OF THE STATE UNIVERSITY OF NEW YORK | 2002-12-31 | — | — | US | disclosed |
| EP-0690856-B1 | ANTI-TUMOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, METHODS FOR PREPARATION THEREOF AND FOR TREATMENT | UNIV NEW YORK STATE RES FOUND (US) | 2002-12-04 | — | — | EP | disclosed |
| US-6458976-B1 | TAXANE ANTICARCINOGENIC AGENTS AND ANTITUMOR AGENTS | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | 2002-10-01 | — | — | US | disclosed |
| US-20020022651-A1 | Taxoid anti-tumor agents and pharmaceutical compositions thereof | SYNPLICITY, INC. | 2002-02-21 | — | — | US | disclosed |
| US-6100411-A | HIGH ACTIVITIES AGAINST DRUG-RESISTANT TUMORS | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2000-08-08 | — | — | US | disclosed |
| US-6096909-A | Taxoid anti-tumor agents and pharmaceutical compositions thereof | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2000-08-01 | — | — | US | disclosed |
| US-5599820-A | Anti-tumor compounds, pharmaceutical compositions, methods for preparation thereof and for treatment | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1997-02-04 | — | — | US | disclosed |
| US-5294737-A | Hydrolysis, cyclization, condensation | THE RESEARCH FOUNDATION STATE UNIVERSITY OF NEW YORK (US) | 1994-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232878-A1 | Taxoid anti-tumor agents and pharmaceutical compositions thereof | TP53, HPGDS, TUBB1 | FABP5 2182/4885FABP7 4058/4885FABP3 3785/4885 |
| US-20020022651-A1 | Taxoid anti-tumor agents and pharmaceutical compositions thereof | TP53, HPGDS, TUBB1 | FABP5 2182/4885FABP7 4058/4885FABP3 3785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.